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Abstract
Under normal conditions, the regeneration of mouse b cells is mainly dependent on their own duplication. Although there
is evidence that pancreatic progenitor cells exist around duct, whether non-b cells in the islet could also potentially
contribute to b cell regeneration in vivo is still controversial. Here, we developed a novel transgenic mouse model to study
the pancreatic b cell regeneration, which could specifically inhibit b cell proliferation by overexpressing p21
cip in b cells via
regulation of the Tet-on system. We discovered that p21 overexpression could inhibit b-cell duplication in the transgenic
mice and these mice would gradually suffer from hyperglycemia. Importantly, the recovery efficiency of the p21-
overexpressing mice from streptozotocin-induced diabetes was significantly higher than control mice, which is embodied
by better physiological quality and earlier emergence of insulin expressing cells. Furthermore, in the islets of these
streptozotocin-treated transgenic mice, we found a large population of proliferating cells which expressed pancreatic
duodenal homeobox 1 (PDX1) but not markers of terminally differentiated cells. Transcription factors characteristic of early
pancreatic development, such as Nkx2.2 and NeuroD1, and pancreatic progenitor markers, such as Ngn3 and c-Met, could
also be detected in these islets. Thus, our work showed for the first time that when b cell self-duplication is repressed by p21
overexpression, the markers for embryonic pancreatic progenitor cells could be detected in islets, which might contribute
to the recovery of these transgenic mice from streptozotocin-induced diabetes. These discoveries could be important for
exploring new diabetes therapies that directly promote the regeneration of pancreatic progenitors to differentiate into islet
b cells in vivo.
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Introduction
For both type 1 and type 2 diabetes mellitus, one of the most
critical pathogeneses is that the number of functional b cells is
inadequate [1]. Transplantation with donor islets has succeeded in
diabetic clinical trials; however, the resources for transplantable
islets are limited [2,3]. Beside islet transplantation therapy,
another potential clinical approach is to stimulate endogenous b-
cell regeneration in diabetic patients [4]. Hence, it is important to
understand the mechanisms that regulate b-cell regeneration in
the islets of diabetic patients.
To study the mechanisms underlying b-cell regeneration,
several experimental models have been developed, including the
chemical induction of diabetes [5], partial pancreatectomy [6],
duct ligation or cellophane wrapping [7] and abnormal expression
of destructive genes such as TGFa [8], diphtheria toxin A [9] and
c-Myc [10]. With these models, previous studies have demon-
strated that the maintenance and regeneration of b cells relies
mainly on the proliferation of terminally differentiated b cells [11].
Further results from label retention analysis also indicate that all b
cells are equal in replication capacity [12]. On the other hand, it
has also been recently demonstrated with a unique mouse model
of pancreatic damage (i.e., partial duct ligation), that the NGN3+
cells in duct lining could reappear in the adult pancreas following
injury and differentiate into new b cells in transplanted mice [13].
Although these two mechanisms (i.e., b-cell self-replication and
reactivation of pancreatic progenitors) for b-cell regeneration have
been demonstrated, there are still no direct evidences to indicate
whether there are progenitor cells in islets, which could be re-
activated for b-cell regeneration.
Here, we develop a novel mouse model that could specifically
inhibit b-cell replication by the inducible expression of p21 in the b
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first time that overexpression of p21 in mice islets could improve
the recovery from streptozotocin-induced diabetes.
Results
Doxycycline-Inducible Regulation of p21 Overexpression
in Islet b Cells
To study whether non-b cells in islets could be activated and
contributed to b cell regeneration in some specific pathologic
conditions such as b cell loss, we generated a double transgenic
mouse model with the Tet-On system (Insulin-rtTA/TET-p21);
the foreign gene p21 is controlled by the RIPII-rtTA promoter.
Therefore, in this transgenic mouse model, doxycycline (dox)
treatment induces the specific overexpression of p21 in islet b cells
(Fig. 1A), which can inhibit the proliferation of b cells, thus
facilitating our study of the mechanism on b-cell regeneration in
islets with pancreatic progenitor or precursor activation (Fig. 1B).
The transgenic mice developed normally without doxycycline
treatment. Exposed to doxycycline for 7 days, these transgenic
mice could be shown to be specifically expressing p21 in adult islet
b cells using immunofluorescence analysis of pancreatic tissue
(Fig. 1C). There was no obvious difference in glucose homeostasis
between Insulin-rtTA/TET-p21 double-transgenic mice and the
wild-type mice (Fig. 1D). Furthermore, although p21 is sometimes
involved in apoptosis, the double transgenic mice treated with
doxycycline for 7 days did not exhibit abnormal level of apoptosis
in islet (Fig. S1A).
P21 Overexpression in b Cells Inhibits b-Cell Proliferation
The rate of pancreatic b-cell replication is extremely slow [14]
(Fig. 1E), but b cells can be coaxed to replicate more quickly by a
variety of maneuvers and physiological stimuli, including subtotal
pancreatectomy [11], in which b-cell regeneration mainly depends
on b-cell self-duplication. Therefore, to explore the question that
whether p21 expression in b cells is sufficient to inhibit their cell
cycle progress, we first induced p21 expression in adult islets in
double transgenic mice with dox treatment, and then performed a
70% partial pancreatectomy (Px) or sham-operation on transgenic
and control mice. The pancreatic remnants (which correspond to
the duodenal pancreas) were analyzed two days after the
operation. BrdU incorporation was utilized to detect the b-cell
replication. We discovered that the replication of b cells was
dramatically decreased in Px transgenic mice overexpressing p21
compared with Px normal mice (single transgenic mice) (Fig. 1E).
Quantification of proliferation percentage using BrdU staining
revealed that b-cell proliferation rates were 5.761.7% in the Px
control group versus 1.761.0% in the Px p21 transgenic groups
(Fig. 1E). These data indicated that b-cell proliferation was limited
by p21 overexpression after pancreatectomy.
To further elucidate whether p21 could repress b-cell
proliferation, we traced the serum glucose levels of p21 transgenic
mice for a long term. Single transgenic littermates were used as
control. After dox administration for 3 months to continuously up-
regulate p21 expression in b cells, these mice gradually suffered
from hyperglycemia (Fig. 1F). TUNEL staining showed that b cells
undergone apoptosis in these transgenic mice (Fig. S1B). This
result also supported that b-cell homeostasis mainly depends on
the maintenance of b cell mass as previously reported [9,11,15,16].
P21 Overexpression Improved the Recovery from
Streptozotocin (STZ) -Induced Diabetes
To further study whether non-b cells contribute to b-cell
regeneration when most b cells were destroyed and failed to
duplicate themselves, we adopted a model of islet injury by
streptozotocin treatment. As a specific b-cell toxin, streptozotocin
can induce b-cell necrosis and diabetes when given as a single
dose, and limited b-cell regeneration after STZ treatment has been
reported [17,18]. Double transgenic mice and control mice (single
transgenic littermate) were supplemented with dox for 8 days, 9
days, 10 days or 14 days respectively, during our experiments to
initiate and maintain P21 expression. At the eighth day of dox
administration, mice were first treated with a high dose of STZ
(200 mg kg
21), and then their weight (Fig. 2A), diabetes-specific
survival capability (Fig. 2B), and serum glucose levels (Fig. 2C)
were measured. Surprisingly, we discovered that the p21-
overexpressing transgenic mice obviously promoted the recovery
from STZ injury (Fig. 2). After the same dose of STZ treatment,
p21-overexpressing mice were far more competent to increase
weight (Fig. 2A), survive (Fig. 2B), and regain normoglycemia
(Fig. 2C) than normal littermates.
We also tried to determine the amount of b-cell regeneration
after STZ treatment. One day after STZ injection, almost all b
cells in islets were eliminated. Sections of pancreas stained with
Insulin revealed that the islets of both p21-overexpressing
transgenic and control mice contained cell debris and scattered
nuclei, instead of stained living cells (Fig. 2D, STZ 1d), as
previously reported [19,20]. Two days after STZ treatment, Islets
of control group also lacked b cells and still contained cellular
debris; in contrast to the control mice, most of the p21-
overexpressing islets contained a number of newborn Insulin-
positive cells two days after STZ treatment (Fig. 2D, STZ 2d).
Seven days after STZ treatment, the average percentage of insulin
positive cell in transgenic islets could restored to 27.163.9%, while
in control mice the percentage only arrived 5.762.9%. Quanti-
fication of b cell area in pancreas also revealed that b cells
regeneration in p21-overexpressing transgenic mice. From the first
day to the seventh day after STZ treatment, the percentage of b
cell area of total pancreas area in transgenic mice was
0.1760.01% (one day), 0.5860.56% (two day), 0.9160.01%
(three day) and 2.4261.13% (seven day) of the islet mass; while the
percentage of control mice was 0.1160.06% (one day),
0.1660.19% (two day), 0.2660.14% (three day) and
0.2160.08% (seven day) of the islet mass (Fig. 2E).
Because the self-duplication of b cells was inhibited in transgenic
mice, this recovery from STZ treatment and emergence of
newborn Insulin-positive cells suggested that mechanisms other
than b-cell self-renewal contributed to b-cell regeneration when b
cells were destroyed.
A Large Population of Proliferating Cells Expressing pdx1
Emerges in the Islets of p21-Overexpressing Mice after
Injury
To define which cells in the islets proliferate and contribute to
b-cell regeneration, we detected proliferating cells in the islets of
p21-overexpressing transgenic mice following STZ injection.
Using BrdU incorporation, we found a large group of
proliferating cells in the islets emerged one day after STZ
treatment, increasing to a peak on the second day, and then
declining (Fig. 2E–F). Two days after STZ treatment, about 25%
cells in islets of p21 overexpressing transgenic mice were
proliferating; while in control mice the percentages were all less
than 4% (Fig. 2E–F). Double-labeling with BrdU and the
endocrine markers including Insulin, Glucagon, Somatostatin,
and pancreatic polypeptide demonstrated that these proliferating
cells were not endocrine cells (Fig. S2, S3), which excluded the
possibility that the burst of unblocked b-cell replication might
happen in transgenic mice with dox treatment. We also checked
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Tubulin, GFAP, vimentin and CD45, but none of the
proliferating cells expressed these markers (Fig. S2B–C). In order
to identify these proliferating cells(i.e. Ki67 positive), we screened
some early transcription factors and putative progenitor markers
in pancreas, and found out about 22% proliferating cells
expressed Pdx-1. However, in the control mice, we did not find
any PDX1+ proliferating cells (Fig. 3A).
Figure 1. Generation of transgenic mice conditionally over-expressing p21 in islets. (A) Schematic of the Tet-on regulated system.
Addition of doxycycline (Dox) to the drinking water of Insulin-rtTA; the TET-p21 double transgenic mice could induce the over-expression of p21
specifically in b cells. (B) Experimental design: Top, under normal conditions, the regeneration of b cells mainly depends on self-replication; below,
when repress the self-duplication of b cells, non-b cells might be re-activated and contribute to the regeneration. (C) Tissue-specific expression of p21
in islet b cells. Six-week old TET-p21 double-transgenic mice or control mice were treated with dox for 7 days and check the expression pattern of p21.
Specific over-expression of p21 in Insulin-expressing cells was confirmed by immunofluorescence staining for p21 (red) and Insulin (green) in TET-p21
double-transgenic mice. Scale bar: 40 mm. (D) In the absence of dox, 5-week-old TET-p21 double-transgenic mice had normal fasting blood glucose
levels and glucose tolerance. Values are mean6SEM (n=6). (E) Left, TET-p21 transgenic Px mice showed fewer BrdU-positive b cells than control Px
mice after 7 days of dox administration, assessed by immunofluorescence staining for Insulin (red) and BrdU (green). Sham-operated mice were used
as negative control, the difference between transgenic Px mice and transgenic sham-operated mice is not statistical significant. Right, Quantification
of the BrdU labeling b cells in double-transgenic Px mice treated with Dox for 7 days is much lower than the cells in control mice. Data are shown as
percentage6SEM of BrdU-labeled cells contributing to the total b-cell population. ***P,0.001, n$8. Scale bar: 50 mm. (F) Blood glucose change
during 3 months of dox administration. Six week old transgenic mice and their littermates were treated with Dox for more than 3 months, during this
period, the blood glucose levels were detected every 7 days, the blood levels of transgenic mice were clearly higher than control littermates. *P,0.05,
n$5. Tg: double transgenic mice, Control: Single-transgenic TET or p21 littermates.
doi:10.1371/journal.pone.0008344.g001
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PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8344Figure 2. P21-overexpresing improved the recovery from STZ-induced diabetes. Following administration of dox for one week, double
transgenic mice and their littermates were treated with 200 mg/kg of STZ and (A) weight, (B) diabetes-specific survival, (C) serum glucose levels were
tested up to 20 days after STZ treatment. Mice were administrated with dox during this experimental process. *P,0.05, n$11. (D) Pancreas tissue
from double transgenic and control mice were collected on day 1, day 2, day 3, day 7 after STZ treatment, assessed by immunofluorescence staining
for insulin (green). Morphometric analysis revealed b-cell destruction one day after STZ treatment (STZ 1d) in p21-overexpressing transgenic mice and
control mice; extensive Insulin-positive b regeneration could be detected in the islet of double transgenic mice two days after STZ treatment (STZ 2d,
STZ3d, STZ 7d) and no Insulin-positive cells could be detected in control mice. Scale bar: 20 mm. (E) Quantifications of b-cell regeneration based on
insulin staining and intact cellular morphology were detected 1, 2, 3, 7 days after the STZ injection and ceaseless dox treatment. *P,0.05, n$3. (F)
Islet cell proliferation after STZ treatment in p21-overexpressing mice and control mice measured by BrdU (green) labeling. In the islets of double
transgenic mice, BrdU incorporated cells emerge one day after STZ treatment, increase dramatically in two days after STZ treatment, and then decline
afterward; in control mice, BrdU incorporated cells are very few all the time. (G) The number of BrdU+ cell in islets on pancreatic tissue sections was
about 5-fold higher in the double transgenic mice versus control pancreas. ***P,0.001, **P,0.01, n$6. Islets were indicated by dashed circle. Tg:
p21-overexpressing transgenic mice, Control: Single-transgenic TET or p21 littermates.
doi:10.1371/journal.pone.0008344.g002
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markers are also expressed in the islets of p21-overexpressing
transgenic mice after STZ induced islet injury (Fig. 3B–C). It has
been demonstrated that CD133 and c-Met are pancreatic
progenitor/stem cell markers [21,22]. In the islets of adult p21-
overexpressing transgenic mice, we detected the expression of
CD133 and c-Met two days after STZ injection. On the contrary,
although expression of CD133 was detected in some duct-like
structures outside of the islets, no CD133- or c-Met-positive cells
could be discovered in the adult islets of single transgenic
littermates after STZ injection (Fig. 3B–C).
More extensive gene-expression profiling showed that Ngn3 and
the transcription factors downstream of Ngn3 (Pax4, Arx, Nkx2.2,
NeuroD1 and Pax6) were also activated in the injured islets of
transgenic mice (Fig. 4). A more than 300-fold increase of Ngn3
expression in transgenic islets was confirmed by Real-time PCR,
which was more than three times higher than that of control mice
after STZ treatment as previously reported [23] (Fig. S4). These
results suggested that when treated with STZ, the islet progenitor
cells of p21-overexpressing transgenic mice might be reactivated.
Cells Co-Expressing Two or Three Kinds of Endocrine
Hormones Are Detected in p21-Overexpressing
Transgenic Mice after Injury
To further investigate the mechanisms that contribute to STZ
resistance in our mouse model, we then studied the structural
changes in islets. The proportions and locations of endocrine
hormones such as Insulin, Glucagon, Somatostatin and pancreatic
polypeptide were checked. After STZ treatment, the proportion of
Glucagon-expressing and Somatostatin-expressing cells increased,
and the morphology of p21-overexpressing islets after injury was
disturbed, in that Insulin-expressing cells were not spatially
surrounded with Glucagon-expressing cells as in normal islet (data
not shown). Endocrine hormone co-expression was detected in this
injury model. One day after STZ treatment, some cells in p21-
overexpressing islets expressed Glucagon and Somatostatin
simultaneously. Two days after STZ treatment, 72.864.9% of
the Glucagon-expressing cells also expressed Somatostatin, and
some cells simultaneously expressed Insulin and Glucagon, or
Insulin and Somatostatin (Fig. 5A–C). A small group of cells
(5.461.4%) even produced Insulin, Glucagon and Somatostatin
(Fig. 5D), whereas in single transgenic mice after STZ, no such cell
were detected (Fig. S5). This group of cells produced two or three
endocrine hormones were also found in mice constitutively
overexpressing p21. However, the number of these immature cells
detected in the STZ-treated p21-overexpressing transgenic mice
was much higher than that in the untreated transgenic mice (data
not shown), which suggesting that islet hormone co-expressing cells
were more strongly activated following islet acute injury.
Discussion
Our study developed a novel transgenic mouse model to explore
whether non-b cells in islets could contribute to b-cell regeneration
when b-cell self-replication was repressed. This transgenic mouse
model could inducibly overexpress p21 under the control of the
Tet-on system specifically in islet b cells, which could inhibit the
replication of b cells directly in vivo. P21 is an inhibitor of the cell
cycle [24,25] and p21 absence in islets had no effects on islet mass
and glucose metabolism [24]. However, we first detected that
Figure 3. Properties of the proliferating cells in p21-overexpressing islets. In addition to persistent administration of dox, double transgenic
mice and their littermates were treated with 200 mg/kg of STZ after p21 over-expression was induced. (A) Two days after STZ treatment, PDX1+ cells
were almost eliminated in the islet of control mice due to b-cell loss; while PDX1+ (red) BrdU+ (green) cells were emerged in the islet of double
transgenic mice. Scale bar: 20 mm. (B) CD133 (red) was detected in islets of p21-overexpressing mice by immunofluorescence but not in control mice.
P21 Tg: p21-overexpressing transgenic mice, Control: Single-transgenic TET or p21 littermates. (C) c-Met (red) was detected in islets of p21-
overexpressing mice by immunofluorescence while no c-Met was expressed in control mice. Scale bar, 50 mm. Islets were indicated by dashed circle.
Tg: p21-overexpressing transgenic mice, Control: Single-transgenic TET or p21 littermates.
doi:10.1371/journal.pone.0008344.g003
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of serum glucose and eventually caused diabetes (Fig. 1F). And our
data demonstrated that overexpression of p21 in the mouse
pancreas efficiently arrested cell cycle and progressively caused
apoptosis (Fig. 1E–F, Fig. S1), similar to its effect in hepatocytes
and renal cells [26,27]. Therefore, our transgenic mouse model
was demonstrated to be valuable for the study of non b-cell
derived b-cell regeneration in islet.
Moreover, we also discovered that this transgenic mouse model
could enhance recovery against STZ-induced diabetes, with lower
blood glucose levels after STZ injury, higher weight and survival
efficiency (Fig. 2A–C). The Insulin-producing cells in the islets of
these transgenic mice could reappear two days after STZ
treatment (Fig. 2D). These phenomena suggest that when b-cell
self-duplication is repressed, islet damage by STZ treatment might
re-activate other mechanisms to induce b-cell regeneration in our
mouse model for diabetic recovery.
We detected a large population of proliferating cells in p21-
overexpressing islets of our mouse model following STZ
injection, which did not express any terminally differentiated
islet cell markers (Fig. S2A) including Insulin (Fig. S3), or the
markers of other differentiated cells, such as neurons (bIII-
Tubulin), glia cells (GFAP), vimentin and blood lineages (CD45)
(Fig. S2B–C). The evidences that these proliferating cells could
undergo significant replication and expressed no differentiated
markers suggests that these cells might be ‘‘transient amplifying
cells’’ in the process of ‘‘stem cellsR transient amplifying cellsR
terminally differentiated cells’’ [28]. Moreover, we demonstrat-
ed that several transcription factors critical for pancreatic
progenitor development were alsou p - r e g u l a t e di nt h ei s l e t so f
our P21 overexpression transgenic mice after STZ treatment
(Fig. 3B–C, Fig. 4, Fig. S4). One of these factors Pdx1 is the key
transcription factor which regulates the embryonic development
of pancreas and expresses widely in the embryonic pancreatic
progenitors [29]. PDX1+Ki67+ cells could be activated in 60%
Px model around duct and after in vitro culture of b cells
[30,31]. Kodama and Araki group also reported that pdx1 and
ngn3 would be activated after STZ treatment, which was related
to beta cell regeneration [23]. Ngn3 is the earliest and specific
islet progenitor marker during embryonic development but do
not express in adult pancreas [32].T h e r e f o r e ,w ep r e s u m e dt h a t
re-expression of ngn3 and other embryonic pancreatic progen-
itor markers such as Pax4, Arx, and Nkx2.2 after STZ induced
islet injury might indicate the islet progenitor reactivation in the
P21 transgenic mice (Fig. 4). In our P21 transgenic mouse
model, Pdx1 could be detected in about 22% proliferating cells
in the islet of STZ treated transgenic mice (Fig. 3A), while Ngn3
was up-regulated more than 300 times in p21 overexpressing
mice after STZ treatment than that of control mice. Ngn3 was
considered to be an unambiguous marker known for islet
progenitors in embryonic [32] and in the adult pancreas [13],
which. Previous studies also showed that c-Met could be
detected around the acini and ducts in normal philosophy, and
CD133 used to isolate pancreatic NGN3+ cells from fetal mice
and humans could be potential pancreatic stem/progenitor cell
markers [21,22]; The expression of these two genes were also
found in the islets of our mouse model after injury. However,
none of these genes expression was detected in the islets of
control mice following STZ injury. Altogether, our results
indicated that the putative progenitor cell activation could be
induced under conditions where b-cell self-duplication is
inhibited.
On the other hand, in the islets of p21-overexpressing transgenic
mice following STZ treatment, we clearly identified simultaneous-
Figure 4. RT-PCR analysis of islets. Six-week-old mice were treated
with dox for 7 days, and then injected with 200 mg/kg STZ. Two days
after STZ treatment, islets are isolated to perform RT-PCR analysis.
Compared to islets of control mice, RT-PCR could detect the expression
of progenitor marker ngn3 and pancreatic transcription factors Pax4,
Arx, Nkx2.2, NeuroD1, Pax6, which regulated by Ngn3, was high in
double transgenic islets two days after STZ treatment. cDNA from adult
mouse islet cells and from E14.5 pancreas served as control. The
negative control (Blank) contained water without cDNA.
doi:10.1371/journal.pone.0008344.g004
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Glucagon and Somatostatin (Fig. 5A–D). It has been demonstrat-
ed that during early pancreas development, there are cells co-
expressing Insulin, Glucagon, and Somatostatin spontaneously,
which are multipotent islet precursors and can differentiate into all
endocrine cell types [33,34]. Therefore, our data suggested that b-
cell regeneration in the adult islets might be the reason of the STZ-
induced diabetic recovery in P21 transgenic mice, which might
involve the activation of early pancreatic developmental pathways.
In summary, our work established a novel transgenic mouse
model to uncover the detailed mechanisms of b-cell regeneration
in islets, which could have critical potential for future diabetes
therapy.
Materials and Methods
Generation of Transgenic Mice
All experiments were approved by the Animal Care and Use
Committee of Peking University. Our Transgenic mouse model
were generated on a pure CD1 background by cross breeding two
transgenic lines of mice: one carrying the p21 regulated by a
bidirectional tetracycline responsive element and the second
expressing the reverse tetracycline transactivator (rtTA) under
the control of the rat insulin II promoter Transmission of both
transgenes was monitored by PCR analysis from tail DNA by
using the following primers:
(1) TCAAAAGCTGGGAGTTGAGC
(2) CTCAGAAGTGGGGGCATAGA
(3) GGATCCTCTAGTCAGCTGAC
(4) GAGGAAGTACTGGGCCTCTT
The transgenes were activated in vivo by administrating 1 mg/
ml of dox in 1% sucrose in the drinking water (the control mice
received only 1% sucrose). Water was changed every 5 days. 6-
week old mice were treated with dox for 7 days to initiate the
expression of p21, and then sacrificed to check for the pattern of
p21 expression. Three independent transgenic mouse lines with
right pattern were used for following studies. Single transgenic
mice were used as control mice.
Figure 5. Immature progenitor state of the islet cells in p21-overexpressing transgenic mice after STZ treatment. (A–C) Representative
confocal images of co-staining with two islet endocrine markers in p21-overexpressing transgenic mice after STZ treatment. Dapi, Blue. (A) The islet
cells co-expressing Insulin (green) and Glucagon (red). (B) The islet cells co-expressing Insulin (green) and Somatostatin (red). (C) The islet cells co-
expressing Glucagon (red) and somatostatin (green). Scale bar: 20 mm. (D) Representative confocal images of Insulin and Glucagon and Somatostatin
co-staining in STZ-injured double transgenic mice. Pancreas sections were stained for dapi (blue), Insulin (green), Glucagon (cyan) and Somatostatin
(red). Arrowhead denotes a cell co-expressing three or two endocrine markers. Scale bar: 16 mm.
doi:10.1371/journal.pone.0008344.g005
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To assess the apoptosis by TUNEL assay, dissected pancreas
were first fixed with 4% paraformaldehyde and then permeabi-
lized with 0.5% TritonX-100. The TUNEL procedure was
performed under the instruction of the DeadEnd fluorometric
TUNEL system (Promega) and then viewed using the normal
Leica microscopy. Positive control cover slips were treated with
DNase I (Promega) prior to the addition of the 39-OH labeling mix
according to the instruction. All samples were analyzed with at
least two biological replicates, and three images from each
replicate.
Pancreatectomy and STZ Treatment
Double transgenic male mice and control mice (single
transgenic male mice) aged 6 weeks were administrated with dox
in the whole process of our experiments. After one week of dox
administration to initiate p21 expression, we performed Px and
STZ injection. For the Px model, these two groups (at least 5 mice
per group) underwent partial (60%) Px and were sham operated.
For the single high-dose STZ model, these two groups (at least 20
mice per group) were injected i.p. with STZ (Sigma) dissolved in
citrate buffer, pH 4.5, at a concentration of 200 mg/kg.
To measure the islet proliferation after treatment, BrdU (Sigma-
Aldrich, 200 mg/kg) was administered 6 h before sacrifice. BrdU
incorporation was assessed using a BrdU-specific mouse antibody
(Zymed). Then BrdU-positive cells and total cell numbers of islet
in the whole randomly selected microscopic fields were counted
from three non-consecutive slides of each mouse. The percentage
of BrdU-positive cells was calculated by the number of BrdU-
positive cells/the total number of islet cells.
Glucose Level Determinations
After 3 months of dox administration or STZ injection, Glucose
levels (mmol/l) of mice were determined with the Accu-Chek
Active meter (ROCHE) with blood sample obtained from the
snipped tail after overnight fast. For intraperitoneal glucose
tolerance test, mice were fasted overnight (16–18 h), then their
fasting basal glucose was measured, and they were injected
intraperitoneally with 25% glucose in saline to a final amount of
2 g glucose/kg body weight. Blood samples were obtained from
the snipped tail at 15, 30, 60, 90, and 120 min after glucose
injection and analyzed.
Immunofluorescence
Mice were killed by cervical dislocation, and then adult tissues
were dissected. Tissues were embedded, frozen in tissue-Tek OCT
compound, and serially sectioned. At least three nonconsecutive
individual sections per animal were selected for each immuno-
staining analysis. For immunoflurescence staining, frozen sections
were rehydrated and washed in PBS, permeabilized with 0.1%
Triton X-100 in PBS (15 minutes, room temperature), and
incubated with primary and secondary antibody (TRITC or
fluorescein or CY5-conjugated). Stained sections were mounted
(Vector) and analyzed on a Leica confocal microscope. The
following primary antibodies were used: guinea pig anti-Insulin
(1:200; DAKO), rabbit anti-Glucagon (1:200; Santa-cruz), goat
anti-Somatostatin (1:200; Santa-cruz), rabbit anti-pancreatic
polypeptide (1:200; Chemicon), mouse anti-BrdU (1:80; Zymed),
mouse anti-ki67 (1:100; DakoCytomation), Rabbit anti-pdx1
(1:200; Abcam), rabbit anti–c-Met (1:150; Santa-cruz), and rabbit
anti-CD133 (1:200; Santa-cruz), rabbit anti-P21 (1:100; Santa-
cruz), mouse anti-Vimentin (1:200; Santa-cruz), rabbit anti-
CD45(1:200; BD), rabbit anti-bIII-Tubulin (1:200; Santa-cruz),
rabbit anti-GFAP (1:200; Santa-cruz). Secondary antibodies were
all from Jackson Immunoresearch Laboratories. For double and
triple staining, only affinity-purified secondary antibodies were
used. Images were viewed using Microscope (Leica DM4000B) or
confocal scanning (Leica DMIRE) microscopy.
Histological Analysis
Quantification evaluation of b-cell area was performed after
insulin staining of pancreas. To measure beta cell mass, three
randomly selected insulin stained pancreas sections from each
mouse (n=3) were imaged. Pancreatic and islet areas were
outlined, quantified and are presented as a ratio as reported
previously by Dr. Cano [35]. To measure the average percentage
of insulin positive cells in islet, more than 60 islets of each mouse
(n=3) were analyzed, calculating the ratio between the area
occupied by insulin-positive cells with intact cellular morphology
and that occupied by the islets.
RT-PCR and Real-Time PCR Analysis
Mouse islets were isolated as described previously [36]. In the
double transgenic mice and control mice two days after STZ
treatment, pancreas were injected through the pancreatic duct
with 3 ml of 1.7 mg/ml Collagenase P (Gibco) in Hanks’ buffered
saline solution (HBSS), removed, incubated at 37uC for 17 min,
and then passed through a 500-mm wire mesh. The digested
pancreas was rinsed with HBSS, and islets were separated by
density gradient in Histopaque (Sigma). After several washes with
HBSS, islets were handpicked under a microscope. After isolation,
islets were aliquoted and stored at 270uC until RNA was isolated.
Semiquantitative RT-PCR was performed using the primer pairs
shown in Table S1. Real-time PCR analysis was performed on
ABI PRISM 7300 Sequence Detection System using the SYBR
Green PCR Master Mix (TOYOBO) by Ngn3 specific primes.
Statistics
All data presented are representative of at least three
independent experiments unless indicated otherwise. The results
are expressed as the mean6SEM of at least three independent
experiments. Statistical analysis was performed using one-way
ANOVA.
In all of the tests, value of P,0.05 was considered significant,
P,0.01 highly significant, and P,0.001extremely significant.
Supporting Information
Figure S1 P21 over-expression caused apoptosis in double
transgenic mice after dox treatment up to 3 months. Six-week-
old mice were treated with doxycycline for one week (A) and 3
months (B), then sacrificed and assessed for apoptotic cell death.
On 7th day, little b cell apoptosis was detected by TUNEL
staining in double-transgenic mice as that in wildtype mice. After 3
months, b cell apoptosis was detected only in transgenic mice.
Pancreatic slides treated with DNase I prior to the addition of the
39-OH labeling mixture were utilized as positive control for this
experiment. Islets were indicated by dashed circle. Scale bar:
50 mm.
Found at: doi:10.1371/journal.pone.0008344.s001 (2.21 MB TIF)
Figure S2 Proliferating cell did not co-stain with markers of
terminally differentiated cells in islet. (A) Double-labeling with
BrdU (red) and endocrine markers (green) such as Insulin,
Glucagon, Somatostatin, and pancreatic polypeptide demonstrat-
ed that these proliferating cells are not endocrine cells - a, b, d or
pancreatic polypeptide cells. (B) Staining with Ki67 (green) and
P21
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are not neurons or astrocytes. (C) Staining with BrdU (red) and
vimentin and CD45 revealed that these proliferating cells are not
hematopoietic cells or mesenchymal cells. Scale bar, 50 mm.
Found at: doi:10.1371/journal.pone.0008344.s002 (0.79 MB TIF)
Figure S3 Proliferating cell did not co-stain with insulin in islet.
Six-week-old mice were treated with dox for 7 days, and then
injected with 200 mg/kg STZ. Two days after STZ treatment,
Double-labeling with BrdU (red) and insulin (green) was checked
by confocal microscopy in STZ treated transgenic islet. Scale bar:
50 mm.
Found at: doi:10.1371/journal.pone.0008344.s003 (0.27 MB TIF)
Figure S4 Real-time PCR result confirmed that the ngn3
transcript increased more than 300 times in dox and STZ treated
transgenic mice, the values were normalized to control mice
without STZ treatment. *P,0.05, n$6
Found at: doi:10.1371/journal.pone.0008344.s004 (0.20 MB TIF)
Figure S5 Islet cells in control mice after STZ treatment (A–C)
Representative confocal images of co-staining with two endocrine
markers. Dapi, Blue. (A) Denotes islets co-stained by Insulin
(green) and Glucagon (red). (B) Denotes cells co-stained by Insulin
(green) and Somatostain (red). (C) Denotes cells co-stained by
Glucagon (red) and Somatostain (green). Scale bar: 20 mm.
Found at: doi:10.1371/journal.pone.0008344.s005 (0.59 MB TIF)
Table S1 Primer sequences in RT-PCR.
Found at: doi:10.1371/journal.pone.0008344.s006 (0.04 MB
DOC)
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